Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -42.01% is 67% below its 5-year average of -25.21%, near the low end of its 5-year range (-46.28%–-6.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.64% below its 12-month average of -39.39%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -42.01%.
RETURN ON EQUITY (ROE)
-42.01%
RETURN ON EQUITY (ROE) AVG TTM
-39.39%
RETURN ON EQUITY (ROE) AVG 3Y
-30.59%
RETURN ON EQUITY (ROE) AVG 5Y
-25.21%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-6.64%
CURRENT VS 3Y AVG
-37.34%
CURRENT VS 5Y AVG
-66.62%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+0.01%
vs the sector median at left
Tyra Biosciences, Inc.
Market Cap
$1.20B
Return on Equity (ROE)
-42.01%
TTM Avg
-39.39%
3Y Avg
-30.59%
5Y Avg
-25.21%
Market Cap
$1.21B
Return on Equity (ROE)
N/A
TTM Avg
-23.25%
3Y Avg
-1.69%
5Y Avg
10.61%
Market Cap
$1.22B
Return on Equity (ROE)
-1.08%
TTM Avg
-6.99%
3Y Avg
-9.25%
5Y Avg
-8.69%
Market Cap
$1.23B
Return on Equity (ROE)
6.53%
TTM Avg
1.49%
3Y Avg
-4.63%
5Y Avg
-8.73%
Market Cap
$1.23B
Return on Equity (ROE)
-36.81%
TTM Avg
-43.14%
3Y Avg
-42.82%
5Y Avg
-37.59%
Market Cap
$1.23B
Return on Equity (ROE)
1.70%
TTM Avg
-39.25%
3Y Avg
-48.34%
5Y Avg
-48.34%
Market Cap
$1.18B
Return on Equity (ROE)
-50.93%
TTM Avg
-117.72%
3Y Avg
-113.46%
5Y Avg
-86.51%
Market Cap
$1.14B
Return on Equity (ROE)
-17.40%
TTM Avg
-189.25%
3Y Avg
-172.42%
5Y Avg
-134.67%
Market Cap
$1.14B
Return on Equity (ROE)
2.51%
TTM Avg
3.60%
3Y Avg
0.50%
5Y Avg
-7.05%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | $1.20B | -42.01% | -39.39% | -30.59% | -25.21% |
| MannKind Corporation (MNKD)vs › | $1.21B | N/A | -23.25% | -1.69% | 10.61% |
| Innovage Holding Corp. (INNV)vs › | $1.22B | -1.08% | -6.99% | -9.25% | -8.69% |
| Cronos Group Inc. (CRON)vs › | $1.23B | 6.53% | 1.49% | -4.63% | -8.73% |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | -36.81% | -43.14% | -42.82% | -37.59% |
| Omada Health (OMDA)vs › | $1.23B | 1.70% | -39.25% | -48.34% | -48.34% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.18B | -50.93% | -117.72% | -113.46% | -86.51% |
| Nektar Therapeutics (NKTR)vs › | $1.14B | -17.40% | -189.25% | -172.42% | -134.67% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | 2.51% | 3.60% | 0.50% | -7.05% |
| Harrow Health, Inc. (HROW)vs › | $1.14B | -244.91% | -17.45% | -30.16% | -48.76% |
ROE
-42.0%
ROA
-38.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -42.01% |
| 2026-03-31 | -33.83% |
| 2025-12-31 | -46.28% |
| 2025-09-30 | -39.81% |
| 2025-06-30 | -35.03% |
| 2025-03-31 | -29.81% |
| 2024-12-31 | -25.20% |
| 2024-09-30 | -23.11% |
| 2024-06-30 | -21.51% |
| 2024-03-31 | -19.35% |
| 2023-12-31 | -33.85% |
| 2023-09-30 | -26.65% |
| 2023-06-30 | -21.19% |
| 2023-03-31 | -21.05% |
| 2022-12-31 | -21.46% |
| 2022-09-30 | -19.56% |
| 2022-06-30 | -16.67% |
| 2022-03-31 | -12.68% |
| 2021-12-31 | -8.71% |
| 2021-09-30 | -6.47% |
